Latest news
Novartis presents new data on early symptom relief and long-term control in complex skin diseases at AAD 2026
Novartis agrees to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipeline
Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa
Manufacturing expansion in the United States
Novartis is expanding our manufacturing and R&D facilities in the US to scale innovation, help patients and create jobs.
Bringing breakthroughs to more patients
At Novartis, we don’t just discover life-changing medicines, we're part of a broader effort to help ensure medicines reach the people who need them most, wherever they live, because the true value of innovation lies in its ability to improve lives.
Annual reporting suite
Explore and download our Annual Report 2025, Report on Nonfinancial Matters 2025 and other reporting documents.